Abstract
Data regarding adipose and serum zinc alpha-2-glycoprotein (ZAG) expression and its association with body composition in patients with advanced chronic kidney disease (CKD) has historically been limited. This study aimed to quantify these expressions and evaluate their associations with longitudinal changes in body composition and mortality in incident dialysis patients. In a single-center prospective cohort study of 148 patients starting peritoneal dialysis, ZAG levels were measured in serum and fat tissue. Results indicated that both adipose and serum ZAG independently predicted adipose tissue mass (ATM). Over one year, adipose ZAG levels predicted changes in both ATM and lean tissue mass (LTM). Furthermore, serum ZAG levels were found to be a robust independent predictor of overall survival and infection-related mortality.
Introduction: Addressing the Obesity Paradox in CKD
Patients transitioning to dialysis for advanced chronic kidney disease (CKD) often face significant shifts in body composition. These changes typically manifest as "protein-energy wasting"—a loss of muscle mass—often accompanied by a paradoxical accumulation of fat. These alterations are not merely cosmetic; they are deeply linked to metabolic complications and increased mortality rates.
A significant hurdle in clinical management is the "obesity paradox." While obesity is a well-known risk factor for cardiovascular disease in the general population, it often appears to have a protective effect in dialysis patients. This phenomenon renders traditional metrics like Body Mass Index (BMI) unreliable for risk stratification. Consequently, there is an urgent need for biomarkers that can more accurately predict wasting and mortality. Zinc alpha-2-glycoprotein (ZAG), an adipokine known for its role in lipid mobilization, emerged as a potential candidate, though its specific role in the context of CKD remained poorly understood.
Methodology and Study Design
The researchers conducted a prospective cohort study at the Prince of Wales Hospital in Hong Kong, recruiting 148 incident peritoneal dialysis (PD) patients. The study employed a multi-modal assessment strategy:
- ZAG Quantification: Adipose ZAG mRNA expression was measured via RT-QPCR from fat samples collected during PD catheter insertion. Serum ZAG levels were measured using ELISA four weeks post-dialysis initiation.
- Body Composition Analysis: Multi-frequency bioimpedance spectroscopy (BCM) was used to quantify Lean Tissue Mass (LTM) and Adipose Tissue Mass (ATM) at baseline and at a one-year follow-up.
- Clinical Follow-up: The primary endpoint was two-year all-cause mortality, with secondary outcomes focusing on longitudinal changes in body composition.
As shown in the flowchart, while 148 patients were initially recruited, follow-up body composition data was available for 117 patients at the one-year mark, providing a robust dataset for longitudinal analysis.
Key Findings: ZAG as a Predictor of Health Outcomes
Baseline and Longitudinal Body Composition
A primary finding of the study was the independent predictive value of both adipose and serum ZAG for baseline fat mass. Specifically, higher levels of ZAG expression were associated with lower adipose tissue mass at the start of the study.
The longitudinal data revealed a significant trend: over the first year of dialysis, patients generally experienced an increase in fat mass (average ATM increase of 3.3 kg). Crucially, high adipose ZAG expression at baseline was a "red flag" for unfavorable shifts, significantly predicting both the gain in ATM and the loss of LTM. This suggests that ZAG may play a role in the degradation of muscle quality, possibly through fatty infiltration.
Survival and Mortality
Perhaps most significantly, serum ZAG levels proved to be a powerful predictor of survival. This association remained significant even after adjusting for confounding factors such as age, albumin levels, and baseline BMI. Lower serum ZAG levels were linked to a higher risk of all-cause mortality and infection-related death. This indicates that serum ZAG captures aspects of patient resilience and metabolic health that are not reflected in traditional physical measurements.
Discussion and Conclusion
The study highlights a notable "disconnect" between local (adipose) and systemic (serum) ZAG levels, suggesting that ZAG functions through both paracrine and endocrine pathways. While adipose ZAG is a superior predictor of physical wasting and fat accumulation, serum ZAG serves as a critical indicator of overall survival.
Despite limitations such as the single-center design and the observational nature of the study, these findings position ZAG as a potent dual-purpose biomarker. Future research should explore whether ZAG-targeted therapies could mitigate the debilitating process of muscle wasting and fat accumulation in the CKD population, potentially improving long-term survival and quality of life for dialysis patients.
Summary updated